Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of Directors
Senior management
Our history
Research and development
Technology platform
Therapeutic areas
Pipeline
Scientific papers and presentations
Partnering
Our approach
Our partnerships
Investors
Financial reports and presentations
Share information
Analyst coverage
Major shareholders
Financial calendar
Corporate governance
Corporate governance statements
Dividend policy
Annual general meeting
Articles of association
Safe harbour statement
Whistleblower policy
Risk management
Investor relations policy
ESG
Email alerts
Newsroom
Press Releases
Image library
Glossary
Email alerts
Careers
Life at Nykode
Meet us
Open positions
Search
Research and development
Scientific papers and presentations
Sharing our discoveries and developments in our tireless pursuit of breakthrough therapies
Newest first
Oldest first
Posters & Papers
Presentations
Search
Reset
05/10/2022
Vaccines Summit – 2022 | Poster: P-005 | Antigen presenting cell targeted T cell DNA vaccine candidate inducing strong and specific cellular responses across multiple T cell epitopes of SARS-COV-2
22/09/2022
A therapeutic antigen-presenting cell-targeting DNA vaccine VB10.16 in HPV16-positive high-grade cervical intraepithelial neoplasia: results from a phase 1/2a trial
01/07/2022
Keystone Symposium: Viral Immunity: Basic Mechanisms and Therapeutic Applications | Poster #: 1040 | A DNA COVID-19 vaccine candidate targeting antigen-presenting cell and adapted to RBD of emerging SARS-CoV-2 variants induced strong cross-neutralizing antibodies and protective immune responses in mice
21/04/2022
World Vaccine Congress | Using the Vaccibody™ platform to create new second and third generation vaccines against COVID
08/04/2022
2022 AACR | Poster #: 2232 | A novel and versatile cytokine empowered DNA vaccine platform with superior immune activating potential
Pages:
1
2
3
4
5
6
7
8
9
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer
